12
Participants
Start Date
June 1, 2003
Study Completion Date
October 31, 2005
ibritumomab tiuxetan (Zevalin®)
Loma Linda University, Loma Linda
North County Oncology, Oceanside
Medical Specialists of Fairfield, Fairfield
Queens Hospital, Honolulu
Northwest Oncology and Hematology, Elk Grove Village
Horizon Oncolgy Center, Lafayette
Specialists in Hematology/Oncology, St Louis
Presbyterian Hospital Cancer Center, Charlotte
Lead Sponsor
Biogen
INDUSTRY